Toyota|$17.71 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$26.30 (¥4,200)-0.87%▼ (in JPY terms)
SoftBank|$24.14 (¥3,855)-0.44%▼ (in JPY terms)
MUFG|$21.93 (¥3,502)+1.95%▲ (in JPY terms)
Keyence|$474.14 (¥75,720)+0.69%▲ (in JPY terms)
Nintendo|$52.42 (¥8,371)-0.96%▼ (in JPY terms)
NTT|$1.02 (¥162)-1.40%▼ (in JPY terms)
Takeda|$41.78 (¥6,673)+1.21%▲ (in JPY terms)
Tokyo Electron|$58.06 (¥9,272)+2.95%▲ (in JPY terms)
Recruit|$110.86 (¥17,705)-1.42%▼ (in JPY terms)
ITOCHU|$14.87 (¥2,375)+0.79%▲ (in JPY terms)
Honda|$11.08 (¥1,769)-4.53%▼ (in JPY terms)
Shin-Etsu|$35.75 (¥5,709)+0.90%▲ (in JPY terms)
Tokio Marine|$3.71 (¥592)+1.30%▲ (in JPY terms)
Fast Retailing|$503.94 (¥80,480)-1.34%▼ (in JPY terms)
Toyota|$17.71 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$26.30 (¥4,200)-0.87%▼ (in JPY terms)
SoftBank|$24.14 (¥3,855)-0.44%▼ (in JPY terms)
MUFG|$21.93 (¥3,502)+1.95%▲ (in JPY terms)
Keyence|$474.14 (¥75,720)+0.69%▲ (in JPY terms)
Nintendo|$52.42 (¥8,371)-0.96%▼ (in JPY terms)
NTT|$1.02 (¥162)-1.40%▼ (in JPY terms)
Takeda|$41.78 (¥6,673)+1.21%▲ (in JPY terms)
Tokyo Electron|$58.06 (¥9,272)+2.95%▲ (in JPY terms)
Recruit|$110.86 (¥17,705)-1.42%▼ (in JPY terms)
ITOCHU|$14.87 (¥2,375)+0.79%▲ (in JPY terms)
Honda|$11.08 (¥1,769)-4.53%▼ (in JPY terms)
Shin-Etsu|$35.75 (¥5,709)+0.90%▲ (in JPY terms)
Tokio Marine|$3.71 (¥592)+1.30%▲ (in JPY terms)
Fast Retailing|$503.94 (¥80,480)-1.34%▼ (in JPY terms)

2026-09-22 Sumitomo Electric Industries,Ltd. “Meta, NEC, and Sumitomo Electric collaborate to build "Petal," the world's first commercial petabit-class optical submarine cable system, which will achieve high-capacity transmission using multi-core fiber technology to meet the communication needs of the AI era.”

2026-09-22 Sumitomo Electric Industries,Ltd. “Meta, NEC, and Sumitomo Electric collaborate to build &quo … 続きを読む

2026-09-22 Otsuka Holdings Co.,Ltd. “Positive results from a Phase 3 trial of urefnersen for amyotrophic lateral sclerosis (ALS) caused by FUS mutations – a steady step forward towards realizing gene-targeted therapy for FUS-ALS patients.”

2026-09-22 Otsuka Holdings Co.,Ltd. “Positive results from a Phase 3 trial of urefnersen for amyotrophic … 続きを読む